These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 7691458)
1. The cost of choice: a price too high in the triple screen for Down syndrome. Elkins TE; Brown D Clin Obstet Gynecol; 1993 Sep; 36(3):532-40. PubMed ID: 7691458 [TBL] [Abstract][Full Text] [Related]
2. Cost and effectiveness of the California triple marker prenatal screening program. Cunningham GC; Tompkinison DG Genet Med; 1999; 1(5):199-206. PubMed ID: 11256673 [TBL] [Abstract][Full Text] [Related]
3. An economic appraisal of alternative pre-natal screening programmes for Down's syndrome. Shackley P; McGuire A; Boyd PA; Dennis J; Fitchett M; Kay J; Roche M; Wood P J Public Health Med; 1993 Jun; 15(2):175-84. PubMed ID: 7688977 [TBL] [Abstract][Full Text] [Related]
4. Prenatal screening using maternal serum alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol: two-year experience in a health maintenance organization. McDuffie RS; Haverkamp AD; Stark CF; Haverkamp C; Barth CK J Matern Fetal Med; 1996; 5(2):70-3. PubMed ID: 8796771 [TBL] [Abstract][Full Text] [Related]
5. Elevated maternal urine level of beta-core fragment of human chorionic gonadotropin versus serum triple test in the second-trimester detection of down syndrome. Bahado-Singh R; Oz U; Rinne K; Hunter D; Cole L; Mahoney MJ; Baumgarten A Am J Obstet Gynecol; 1999 Oct; 181(4):929-33. PubMed ID: 10521756 [TBL] [Abstract][Full Text] [Related]
6. Prenatal screening for fetal aneuploidy in singleton pregnancies. Chitayat D; Langlois S; Douglas Wilson R; ; J Obstet Gynaecol Can; 2011 Jul; 33(7):736-750. PubMed ID: 21749752 [TBL] [Abstract][Full Text] [Related]
7. Periodic health examination, 1996 update: 1. Prenatal screening for and diagnosis of Down syndrome. Canadian Task Force on the Periodic Health Examination. Dick PT CMAJ; 1996 Feb; 154(4):465-79. PubMed ID: 8630836 [TBL] [Abstract][Full Text] [Related]
9. Triple marker (alpha-fetoprotein, unconjugated estriol, human chorionic gonadotropin) versus alpha-fetoprotein plus free-beta subunit in second-trimester maternal serum screening for fetal Down syndrome: a prospective comparison study. Kellner LH; Weiner Z; Weiss RR; Neuer M; Martin GM; Mueenuddin M; Bombard A Am J Obstet Gynecol; 1995 Oct; 173(4):1306-9. PubMed ID: 7485343 [TBL] [Abstract][Full Text] [Related]
10. Maternal serum screening for fetal Down syndrome in women less than 35 years of age using alpha-fetoprotein, hCG, and unconjugated estriol: a prospective 2-year study. Phillips OP; Elias S; Shulman LP; Andersen RN; Morgan CD; Simpson JL Obstet Gynecol; 1992 Sep; 80(3 Pt 1):353-8. PubMed ID: 1379701 [TBL] [Abstract][Full Text] [Related]
11. [The triple test scenario for Styria. With data of the Styria Abnormalities Register]. Häusler MC; Berghold A; Zierler H; Behmel A; Pertl B Gynakol Geburtshilfliche Rundsch; 1996; 36(3):169-77. PubMed ID: 9172798 [TBL] [Abstract][Full Text] [Related]
12. Comparison of urinary hyperglycosylated human chorionic gonadotropin concentration with the serum triple screen for Down syndrome detection in high-risk pregnancies. Bahado-Singh RO; Oz U; Shahabi S; Mahoney MJ; Baumgarten A; Cole LA Am J Obstet Gynecol; 2000 Nov; 183(5):1114-8. PubMed ID: 11084551 [TBL] [Abstract][Full Text] [Related]
13. Prenatal diagnosis of diverse chromosome abnormalities in a population of patients identified by triple-marker testing as screen positive for Down syndrome. Benn PA; Horne D; Briganti S; Greenstein RM Am J Obstet Gynecol; 1995 Aug; 173(2):496-501. PubMed ID: 7544068 [TBL] [Abstract][Full Text] [Related]
14. Estimates for the sensitivity and false-positive rates for second trimester serum screening for Down syndrome and trisomy 18 with adjustment for cross-identification and double-positive results. Benn PA; Ying J; Beazoglou T; Egan JF Prenat Diagn; 2001 Jan; 21(1):46-51. PubMed ID: 11180240 [TBL] [Abstract][Full Text] [Related]
15. An economic appraisal of screening for Down's syndrome in pregnancy using maternal age and serum alpha fetoprotein concentration. Gill M; Murday V; Slack J Soc Sci Med; 1987; 24(9):725-31. PubMed ID: 2440113 [TBL] [Abstract][Full Text] [Related]
16. A prospective evaluation of a second-trimester screening test for fetal Down syndrome using maternal serum alpha-fetoprotein, hCG, and unconjugated estriol. Cheng EY; Luthy DA; Zebelman AM; Williams MA; Lieppman RE; Hickok DE Obstet Gynecol; 1993 Jan; 81(1):72-7. PubMed ID: 7677967 [TBL] [Abstract][Full Text] [Related]
17. MOMs (multiples of the median) and DADs (discriminant aneuploidy detection): improved specificity and cost-effectiveness of biochemical screening for aneuploidy with DADs. Evans MI; Chik L; O'Brien JE; Chin B; Dvorin E; Ayoub M; Krivchenia EL; Ager JW; Johnson MP; Sokol RJ Am J Obstet Gynecol; 1995 Apr; 172(4 Pt 1):1138-47; discussion 1147-9. PubMed ID: 7537020 [TBL] [Abstract][Full Text] [Related]
18. Down syndrome: prenatal risk assessment and diagnosis. Newberger DS Am Fam Physician; 2000 Aug; 62(4):825-32, 837-8. PubMed ID: 10969860 [TBL] [Abstract][Full Text] [Related]
19. A prenatal trisomy 21 screening program using alpha-fetoprotein, human chorionic gonadotropin, and free estriol assays on maternal dried blood. Verloes A; Schoos R; Herens C; Vintens A; Koulischer L Am J Obstet Gynecol; 1995 Jan; 172(1 Pt 1):167-74. PubMed ID: 7531397 [TBL] [Abstract][Full Text] [Related]
20. [Evaluation of the value of triple diagnosis in prenatal medicine]. Krebs D Zentralbl Gynakol; 1995; 117(3):130-3. PubMed ID: 7537933 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]